AccessibilityHelpAbout Us
Orexo Ab (publ) logo

Orexo Ab (publ)(OTC) ORXOY

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-94%
5 Year-66%
1 Year-44%
1 Month-21%
$1.39
+0.00%
+0.00Today
Orexo Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 1.392026-09-08
Orexo Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.47%USD 1.772026-08-28
1 month-21.47%USD 1.772026-07-21
3 month-22.78%USD 1.802026-06-10
Year to date-46.54%USD 2.602025-12-17
1 year-43.84%USD 2.482025-09-05
3 year+82.89%USD 0.762023-08-21
5 year-66.34%USD 4.132021-09-01
Since inception-94.39%USD 24.792013-11-27

Orexo Ab (publ) Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 129.67M

Net Income (TTM)

-SEK 308.49M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.11 (Low)

Price

$1.39

Volume

6,989

Open

$1.39

Previous Close

$1.39

Daily Range

$1.39 - $1.39

52-Week Range

$1.36 - $4.05

Estimated Earnings Date

Oct 22, 2026

ORXOY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Orexo Ab (publ)

Orexo AB (publ) is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceuticals and digital therapies. The company operates primarily in the United States, European Union, and the United Kingdom, addressing critical health issues such as opioid use disorder and insomnia.

Products and Services
  • Zubsolv tablets for opioid use disorder treatment
  • Abstral for breakthrough cancer pain management
  • Digital therapies including deprexis for depression
Growth Outlook
  • Expansion of digital therapy offerings is anticipated to drive revenue growth
  • Development of new products like OX124 and OX640 is underway
  • Strategic collaborations may enhance market reach and innovation
Financial Highlights
  • Recent quarterly revenue of 3.5 million SEK, showing a focus on recovery
  • Trailing twelve months (TTM) gross profit margin at 84.67%
  • Cash and cash equivalents of 276.9 million SEK provide operational stability
Orexo AB (publ) has established itself as a key player in the pharmaceutical industry, particularly in the treatment of opioid use disorder and related conditions. The company's flagship product, Zubsolv, has gained traction in the market, contributing to its revenue streams. Additionally, the introduction of digital therapies positions Orexo to meet the growing demand for innovative treatment solutions. The growth outlook for Orexo appears promising, with ongoing development of new products and potential collaborations that could expand its market presence. The recent financial performance indicates a commitment to recovery, with a notable gross profit margin that reflects operational efficiency. The substantial cash reserves provide a buffer for future investments and operational needs, enhancing the company's ability to navigate challenges in the pharmaceutical landscape. Overall, Orexo AB (publ) presents an intriguing opportunity for investors interested in the healthcare sector, particularly in companies focused on innovative solutions for pressing health issues.
AI Generated • Aug 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Uppsala, UP 11148, SE

ORXOY Financials

Key Financial Metrics (TTM)

Gross Margin

84.67%

Operating Margin

-239.92%

Net Income Margin

-236.32%

Return on Equity

-136.72%

Return on Capital

-35.30%

Return on Assets

-59.93%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

6.99K

Avg. Volume

179.238

Financials (TTM)

Gross Profit

SEK 75.16M

Operating Income

-SEK 304.84M

EBITDA

-SEK 240.66M

Operating Cash Flow

SEK 16.31M

Capital Expenditure

-SEK 1.80M

Free Cash Flow

-SEK 1.78M

Cash & ST Invst.

SEK 276.90M

Total Debt

SEK 9.90M

Orexo Ab (publ) Performance Analysis

Orexo Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-0.3%
Q42025-12-31-97.2%
Q12026-03-3151.9%
Q22026-06-30-30.0%
Orexo Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3026.1%
Q42025-12-31-49.4%
Q12026-03-31-136.2%
Q22026-06-306.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 3.50M

-97.0%

Gross Profit

SEK 3.40M

-96.9%

Gross Margin

97.14%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

74

N/A

Net Income

-SEK 100.40M

-152.3%

EBITDA

-SEK 95.00M

-840.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 276.90M

+128.3%

Total Debt

SEK 9.90M

-98.0%

Accounts Receivable

SEK 103.00M

-50.6%

Inventory

SEK 0.00

-100.0%

Long Term Debt

SEK 2.80M

-99.4%

Short Term Debt

SEK 7.10M

-66.0%

Return on Assets

-59.93%

N/A

Return on Invested Capital

-1.10%

N/A

Free Cash Flow

-SEK 108.80M

-15442.9%

Operating Cash Flow

-SEK 90.81M

-12872.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AAWHAscend Wellness Holdings, Inc.
$0.52+6.81%
HLTRFHLS Therapeutics Inc.
$2.82+6.82%
JUSHFJushi Holdings Inc.
$0.42+2.53%
CBWTFAuxly Cannabis Group Inc.
$2.37-0.04%

Trending Stocks

Symbol / CompanyPricePrice Chg
KHCKraft Heinz
$24.60+0.01%
ACVAACV Auctions
$10.41+0.44%
TNONTenon Medical
$5.93+0.12%
ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF
$19.16+0.03%

Questions About ORXOY

What is the current price of Orexo Ab (publ)?

Orexo Ab (publ) is trading at $1.39 per share.

What is the 52-week range for Orexo Ab (publ)?

Over the past 52 weeks, Orexo Ab (publ) has traded between $1.36 and $4.05.

How much debt does Orexo Ab (publ) have?

Orexo Ab (publ) total debt is unavailable.

How much cash does Orexo Ab (publ) have on hand?

Orexo Ab (publ) does not have cash on hand data available.

What is Orexo Ab (publ)’s dividend yield?

Orexo Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services